Chronic idiopathic myelofibrosis: Independent prognostic importance of bone marrow microvascular density evaluated by CD105 (endoglin) immunostaining

Modern Pathology

Volumn 17, Issue 12, 2004, Pages 1513-1520

  Ponzoni, Maurilio ^a,e   Savage, David G ^b   Ferreri, Andrés J M ^a   Pruneri, Giancarlo ^c   Viale, Giuseppe ^c   Servida, Paolo ^a   Bertolini, Francesco ^c   Orazi, Attilio ^d  

^a SAN RAFFAELE HOSPITAL   (Italy)

^b Coll of Phys/Surgs Columbia Univ ^*  (United States)

^c EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^d INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e Ctr of Cell and Molec Pharmacol   (Italy)

Author keywords

Bone marrow; CD105; Endoglin; Myelofibrosis; Prognosis

Indexed keywords

CD34 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; ENDOGLIN; RETICULIN;

ADULT; AGED; ARTICLE; BONE MARROW; BONE MARROW BIOPSY; CHRONIC IDIOPATHIC MYELOFIBROSIS; CLINICAL FEATURE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG TARGETING; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MALE; MEGAKARYOCYTE; MICROVASCULATURE; MULTIVARIATE ANALYSIS; MYELOFIBROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, CD; ANTIGENS, CD34; BLOOD VESSELS; BONE MARROW; CHRONIC DISEASE; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; MYELOFIBROSIS; PROGNOSIS; RECEPTORS, CELL SURFACE; SURVIVAL ANALYSIS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 10344242385     PISSN: 08933952     EISSN: None     Source Type: Journal    
DOI: 10.1038/modpathol.3800224     Document Type: Article

References (50)

1. Thiele J, Pierre R, Imbert M, et al. Chronic idiopathic myelofibrosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JM (eds). Tumors of Haematopoietic and Lymphoid Tissues. IARC Press: Lyon, France, 2001, pp 35-38.
2. Guardiola P, Anderson JE, Bandini G, et al. Allogeneic stem cell transplantation for agnogenic myeloid metaplasia: a European Group for Blood and Marrow transplantation, Societe Française de Greffe de Moelle, Gruppo Italiano per il Trapianto del Midollo Osseo, and Fred Hutchinson Cancer Research Center Collaborative Study. Blood 1999;93:2831-2838.
3. Anderson JE, Deeg HJ, Tefferi A, et al. Effective treatment of myelofibrosis (MF) by autologous peripheral blood stem cell (PBSC) transplantation (PBSCT). Blood 1999;94:396a (abstract).
4. Kerbel R, Folkman J. Clinical translation of angiogenesis inhibitors. Nat Rev Cancer 2002;2:727-739.
5. Lundberg LG, Lerner R, Sundelin P, et al. Bone marrow in polycythemia vera, chronic myelocytic leukemia and myelofibrosis has an increased vascularity. Am J Pathol 2000;157:15-19.
6. Bertolini F, Mancuso P, Gobbi A, et al. The thin red line: angiogenesis in normal and malignant hematopoiesis. Exp Hematol 2000;28:993-1000.
7. Di Raimondo F, Azzaro MP, Palumbo GA, et al. Elevated vascular endothelial growth factor (VEGF) serum levels in idiopathic myelofibrosis. Leukemia 2001;15:976-980.
8. Mesa RA, Hanson CA, Rajkumar SV, et al. Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia. Blood 2000;96:3374-3380.
9. Mesa RA, Steensma DP, Pardanani A, et al. A phase II study trial of combination low-dose thalidomide and prednisone for the treatment of myelofibrosis with myeloid metaplasia. Blood 2003;101:2534-2541.
10. Tanaka FT, Otake Y, Yanagihara K, et al. Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 2001;7:3410-3415.
11. Kumar S, Ghellal A, Li C, et al. Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 1999; 59:856-861.
12. Calabrò L, Fonsatti E, Bellomo G, et al. Differential levels of soluble endoglin (CD105) in myeloid malignancies. J Cell Physiol 2003;194:171-175.
13. Bauermeister DE. Quantification of bone marrow a-a normal range. Am J Clin Pathol 1971;56:24-31.
14. Pruneri G, Bertolini F, Soligo D, et al. Angiogenesis in myelodysplastic syndromes. Br J Cancer 1999;81: 1398-1401.
15. Perez-Atayde AR, Sallan SE, Tedrow U, et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997;150:815-821.
16. Padrò T, Ruiz S, Bieker R, et al. Increased angiogenesis in the bone marrow of patients with acute myeloid leukemia. Blood 2000;95:2637-2644.
17. de Bont ES, Rosati S, Jacobs S, et al. Increased bone marrow vascularization in patients with acute myeloid leukemia: a possible role for vascular endothelial growth factor. Br J Haematol 2001;113: 296-304.
18. Korkolopoulou P, Apostolidou E, Pavlopoulos PM, et al. Prognostic evaluation of the micro vascular network in myelodysplastic syndromes. Leukemia 2001;15:1369-1376.
19. Doussis-Anagnostopoulou IA, Talks KL, Turley H, et al. Vascular endothelial growth factor (VEGF) is expressed by neoplastic Hodgkin-Reed- Sternberg cells in Hodgkin's disease. J Pathol 2002;197:677-683.
20. Munshi NC, Wilson C. Increased bone marrow micro vessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001;28: 565-569.
21. Rajkumar SV, Mesa RA, Fonseca R, et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undeterminate significance, multiple myeloma and primary amyloidosis. Clin Cancer Res 2002;8:2210-2216.
22. Sezer O, Niemoller K, Kaufmann O, et al. Decrease of bone marrow angiogenesis in myeloma patients achieving a remission after chemotherapy. Eur J Hematol 2001;66:238-244.
23. Kumar S, Fonseca R, Dispenzieri A, et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 2002;119:665-671.
24. Pruneri G, Ponzoni M, Ferreri AJ, et al. Micro vessel density, a surrogate marker of angiogenesis, is an independent predictor of survival in multiple myeloma patients. Br J Haematol 2002;118:817-820.
25. Choi JH, Ahn MJ, Jang SJ, et al. Absence of clinical prognostic value of vascular endothelial growth factor and micro vessel density in multiple myeloma. Int J Hematol 2002;76:460-464.
26. Vacca A, Ribatti D, Ruco L, et al. Angiogenesis extent and macrophage density increase simultaneously with pathological progression in B-cell non-Hodgkin's lymphomas. Br J Cancer 1999;79:965-970.
27. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000;14:1414-1418.
28. Arias V, Soares FA. Vascular density (tumor angiogenesis) in non-Hodgkin's lymphomas and florid follicular hyperplasia: a morphometric study. Leukemia Lymphoma 2000;40:157-166.
29. Ridell B, Norrby K. Intratumoral vascular density in malignant lymphomas of B-cell origin. APMIS 2001;109:66-72.
30. Molica S, Vacca A, Ribatti D, et al. Prognostic value of enhanced bone marrow angiogenesis in early B-cell chronic lymphocytic leukemia. Blood 2002;100: 3344-3351.
31. Pazgal I, Zimra Y, Tzabar C, et al. Expression of basic fibroblastic growth factor is associated with poor outcome in non-Hodgkin's lymphomas. Br J Cancer 2002;86:1770-1775.
32. Wimazal F, Jordan JH, Sperr WR, et al. Increased angiogenesis in the bone marrow of patients with systemic mastocytosis. Am J Pathol 2002;160: 1639-1645.
33. Mesa RA, Hanson CA, Li CY, et al. Diagnostic and prognostic value of bone marrow angiogenesis and megakaryocyte c-Mpl expression in essential thrombocytemia. Blood 2002;99:4131-4137.
34. Orazi A, Shendrik I, Servida P, et al. Angiogenesis in agnogenic myeloid metaplasia. Mod Pathol 2001;14: 175A (abstract).
35. Fonsatti E, Del Vecchio L, Altomonte M, et al. Endoglin: an accessory component of the TGF-beta-binding receptor-complex with diagnostic, prognostic, and bioimmunotherapeutic potential in human malignancies. J Cell Physiol 2001;188:1-7.
36. Guerrero-Esteo M, Sanchez-Elsner T, Letamendia A, et al. Extracellular and cytoplasmic domains of endoglin interact with the transforming growth factor-beta receptors I and II. J Biol Chem 2002;277: 29197-29209.
37. Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth-factor β and megacaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol 1994;88:9-16.
38. Bock O, Schlu J, Reising D, et al. Expression of fibrogenic cytokines in bone marrow cells from chronic myeloproliferative disorders. J Clin Pathol 2002;55:10a (abstract).
39. Wickenhauser C, Hillienhof A, Jungheim K, et al. Detection and quantification of transforming growth factor and platelet-derived growth factor release by normal human megakaryocytes. Leukemia 1995;9: 13-15.
40. Schmitz B, Thiele J, Kaufmann R, et al. Megakaryocytes and fibroblast-interaction as determined in human bone marrow specimens. Leuk Res 1995;19: 629-637.
41. Michiel DF, Oppenheim JJ. Cytokines as positive and negative regulation of tumor formation and progression. Semin Cancer Biol 1992;3:3-15.
42. Pustzai L, Lewis CE, Lorenzen J, et al. Growth factors: regulation of normal and neoplastic growth. J Pathol 1993;169:191-201.
43. Schmitz B, Wickenhauser C, Thiele J, et al. Megakaryocyte induced fibroblast proliferation is enhanced by costimulation with IL-6/IL-3 and dependent on secretory and adhesion events. Leuk Res 1999;23: 723-729.
44. Thiele J, Kvaniscka HM, Boelthen B. Resident bone marrow macrophages in idiopathic (primary) myelofibrosis (IMF): a histochemical and morphometric study on sequential trephine biopsies. Leuk Res 1999;23: 983-985.
45. Chou JM, Li C-Y, Tefferi A. Bone marrow immunohistochemical studies of angiogenic cytokines and their receptors in myelofibrosis with myeloid metaplasia. Leuk Res 2003;27:499-504.
46. Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia. A pilot study. Leukemia 2002;16:1609-1614.
47. Takahashi N, Haba A, Matsuno F, et al. Antiangiogenic therapy of established tumors in human skin/severe combined immunodeficiency mouse chimeras by anti-endoglin (CD105) monoclonal antibodies, and synergy between anti-endoglin antibody and cyclophosphamide. Cancer Res 2001;61:7846-7854.
48. Fonsatti E, Altomonte M, Arslan P, et al. Endoglin (CD105): a target for anti-angiogenetic cancer therapy. Curr Drug Targets 2003;4:291-296.
49. Seon BK. Expression of endoglin (CD105) in tumor blood vessels. Int J Cancer 2002;99:310-311.
50. Balza E, Castellani P, Zijlstra A, et al. Lack of specificity of endoglin expression for tumor blood vessels. Int J Cancer 2001;94:579-585.